Research and Markets: Metastatic Pancreatic Cancer - Pipeline Review, H2 2014

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/wqdd7q/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H2 2014" report to their offering.

This 'Metastatic Pancreatic Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Mentioned:

  • F. Hoffmann-La Roche
  • AstraZeneca
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Gilead Sciences
  • Merck & Co
  • FibroGen
  • Novartis AG
  • Pfizer Inc.
  • Silence Therapeutics plc
  • Celgene Corporation
  • Bayer AG
  • Incyte Corporation
  • Halozyme Therapeutics, Inc.
  • Momenta Pharmaceuticals, Inc.
  • Immunomedics, Inc.
  • Oncolytics Biotech Inc.
  • Synta Pharmaceuticals Corp.
  • NanoCarrier Co., Ltd.
  • Rexahn Pharmaceuticals, Inc.
  • Colby Pharmaceutical Company
  • INSYS Therapeutics, Inc.
  • OncoMed Pharmaceuticals, Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Cornerstone Pharmaceuticals, Inc.
  • Pharma Mar, S.A.
  • Oncovir, Inc.
  • Cantex Pharmaceuticals, Inc.
  • Regulon Inc.
  • Fountain Biopharma Inc.
  • Oncozyme Pharma Inc.
  • AbbVie Inc.
  • Precision Biologics, Inc.

For more information visit http://www.researchandmarkets.com/research/wqdd7q/metastatic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology